Results 11 to 20 of about 410,320 (404)
Biomarkers in Heart Failure with Preserved Ejection Fraction
Cardiac Failure Review, 2022 Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous disorder developing from multiple aetiologies with overlapping pathophysiological mechanisms.
Antoni Bayes-Genis +5 more
doaj +5 more sources
Treatment of Heart Failure with Preserved Ejection Fraction [PDF]
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011 Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90240/1/phco.31.3.312 ...
Barnes, Megan M. +4 more
core +6 more sources
Treatment of heart failure with preserved ejection fraction
Monaldi Archives for Chest Disease, 2018 Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to high mortality and the frequent need for hospitalization, with a consequent heavy burden on healthcare resources.
Alfredo Monteverde +4 more
doaj +8 more sources
Heart Failure with Preserved Ejection Fraction [PDF]
Current Emergency and Hospital Medicine Reports, 2019 Heart failure with preserved ejection fraction (HFpEF), formerly known as diastolic heart failure, is a chronic disease that affects millions of people around the world.
Ryan, Abigalle
core +4 more sources
Heart failure with preserved ejection fraction [PDF]
Pflügers Archiv - European Journal of Physiology, 2014 Heart failure (HF) is a clinical syndrome of diverse etiologies and can be associated with preserved, reduced, or mid-range ejection fraction (EF). In the community, heart failure with preserved ejection fraction (HFpEF) is emerging as the most common form of HF.
Margaret M. Redfield +2 more
+15 more sources
One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction [PDF]
, 2016 Background—Heart failure with preserved ejection fraction has a complex pathophysiology and remains a therapeutic challenge. Elevated left atrial pressure, particularly during exercise, is a key contributor to morbidity and mortality.
Bergmann, Martin +23 more
core +14 more sources
Journal of Cardiovascular Development and Disease, 2023 (1) Background: Chronic inflammation and fibrosis are key players in cardiac remodeling associated with left ventricular hypertrophy (LVH) and heart failure with a preserved ejection fraction (HFpEF). Monocytes and T-helpers (Th) are involved in both pro-
Artem Ovchinnikov +6 more
doaj +1 more source
Heart failure with preserved ejection fraction [PDF]
Clinical Medicine, 2018 Heart failure with preserved ejection fraction (HFpEF) represents a heterogeneous collection of conditions that are unified by the presence of a left ventricular ejection fraction ≥50%, evidence of impaired diastolic function and elevated natriuretic peptide levels, all within the context of typical heart failure signs and symptoms.
Harper, AR, Patel, HC, Lyon, AR
openaire +6 more sources
Frontiers in Cardiovascular Medicine, 2022 BackgroundAlthough the predictive value of galectin-3 for heart failure with preserved ejection fraction has been demonstrated, the diagnostic value remains unclear.
Jing Jiang +5 more
doaj +1 more source
Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 The findings of randomized trials of neurohormonal modulation have been neutral in heart failure with preserved ejection fraction and consistently positive in heart failure with reduced ejection.
Rohan Samson, Thierry H. Le Jemtel
doaj +1 more source